BioCardia - BCDA Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BCDA shares.
View BCDA analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price targets for BioCardia's stock. Their BCDA share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 221.8% from the stock's current price.
View analysts price targets for BCDA or view top-rated stocks among Wall Street analysts.

BioCardia's stock was trading at $1.94 at the beginning of the year. Since then, BCDA shares have increased by 4.1% and is now trading at $2.02.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BCDA earnings forecast.

BioCardia, Inc. (NASDAQ:BCDA) posted its earnings results on Wednesday, August, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.14. The firm earned $0.97 million during the quarter, compared to analyst estimates of $0.19 million. BioCardia had a negative trailing twelve-month return on equity of 126.57% and a negative net margin of 619.91%. During the same period in the previous year, the business earned ($0.20) EPS.

Shares of BioCardia reverse split before market open on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), American Manganese (AMY) and

(BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

BioCardia trades on the NASDAQ under the ticker symbol "BCDA."

BioCardia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Duckers, Jim L Allen and Peter Altman.
View institutional ownership trends.

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCDA stock can currently be purchased for approximately $2.02.

BioCardia (NASDAQ:BCDA) has a market capitalization of $35.87 million and generates $1.01 million in revenue each year. The company earns $-12,620,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The official website for the company is www.biocardia.com. The company can be reached via phone at (650) 226-0120, via email at investors@biocardia.com, or via fax at 310-861-5299.